Related resources and publications
Assess T-cell engager in BRGSF-HIS
T-cell engager CD3
![](https://cdn.prod.website-files.com/655dd3c88278aa64954052d4/667c287be95f147849d772c9_astrazeneca-poster-sitc2023-cd3_preview.webp)
CD3 binding T-cell engagement
hCD3ε immunocompetent mice enable the preclinical in vivo efficacy assessment of T-cell engagers, to study cancer cell recognition, immunosuppressant therapies, etc.
This model is available on different genetic backgrounds.
(A) Freshly isolated thymocytes from wild-type (WT) and humanized homozygous CD3ε (hCD3ε) mice were analyzed by flow cytometry and gated on single live CD4+CD8+ (DP), CD4+CD8- (CD4 SP), CD4-CD8+ (CD8 SP), CD4-CD8- (DN)
(B) Freshly isolated splenocytes from wild-type (WT) and humanized homozygous CD3ε (hCD3ε) mice were analyzed by flow cytometry and T-cell subsets were gated on single live TCRβ+, TCRɣẟ+, CD4-CD8+ (CD8), CD4+CD8-FoxP3- (Conv CD4), CD4+CD8-FoxP3+ (Treg)
(A) Freshly isolated splenocytes from wild-type (WT) and humanized homozygous CD3ε (hCD3ε) mice were incubated with anti-human CD3 antibody (clone SP34) and were analyzed by flow cytometry and gated on single live CD4+CD8-FoxP3- (Conv CD4), CD4-CD8+ (CD8), CD4+CD8-FoxP3+ (Treg)
(B) Isolated T cells were labelled with CTV and activated with various concentrations of coated anti human CD3 (SP34) for 72h
(C) Isolated T cells were activated with various concentration of coated anti human CD3 (SP34) for 72h. IFN-ɣ level in supernatant was quantified by ELISA
T-cell engagers efficacy assessment. (A) Experimental design for in vivo experiments. Tumor growth curves in (B) wild-type and (C) hCD3ε mice.
Assess T-cell engager in BRGSF-HIS
T-cell engager CD3
CD3 binding T-cell engagement
Let us know how we can help
Physiological relevance
Comprehensive and reliable validation data
Over 600 scientific articles based on our models
In-depth expertise in preclinical science, physiology, and model development
Unique R&D platform located in France
Tailor-made approach to your needs
Strong emphasis on customer satisfaction
Long-standing partnerships with 17 of the top 20 pharma companies
Co-development of innovative models for next-generation drugs
Guaranteed FTO/freedom to operate